EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

A phase 2 trial of mini‐hyper‐ CVD , blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia

Wei-Ying Jen iD, Elias Jabbour iD, Nicholas J Short iD, Ghayas C Issa iD, Fadi G Haddad iD, Nitin Jain iD, Naveen Pemmaraju iD, Naval G Daver iD, Lucia Masarova iD, Gautam Borthakur iD, Kelly Chien iD, Rebecca Garris und 1 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27463 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Wei-Ying Jen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Pyridazines, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Imidazoles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Takeda Oncology, University of Texas MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificPyridazinesPrecursor Cell Lymphoblastic Leukemia-LymphomaImidazolesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAdultMaleMiddle AgedAgedYoung AdultLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSurvival Rate

Substanzen

blinatumomabAntibodies, BispecificponatinibPyridazinesImidazoles

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Wei-Ying Jen, Elias Jabbour, Nicholas J Short, Ghayas C Issa, Fadi G Haddad, Nitin Jain, Naveen Pemmaraju, Naval G Daver, Lucia Masarova, Gautam Borthakur, Kelly Chien, Hagop M Kantarjian

Förderung

  • NCI NIH HHS
  • Takeda Oncology
  • University of Texas MD Anderson Cancer Center
  • Amgen

Zitieren

APA

Jen, W. Y., Jabbour, E., Short, N. J., Issa, G. C., Haddad, F. G., Jain, N., Pemmaraju, N., Daver, N. G., Masarova, L., Borthakur, G., Chien, K., Garris, R., & Kantarjian, H. M. (2024). A phase 2 trial of mini‐hyper‐ CVD , blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American Journal of Hematology. https://doi.org/10.1002/ajh.27463

Vancouver

Jen WY, Jabbour E, Short NJ, Issa GC, Haddad FG, Jain N, et al. A phase 2 trial of mini‐hyper‐ CVD , blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American Journal of Hematology. 2024. doi:10.1002/ajh.27463

BibTeX
@article{Jen2024,
  author = {Jen, Wei-Ying and Jabbour, Elias and Short, Nicholas J and Issa, Ghayas C and Haddad, Fadi G and Jain, Nitin and Pemmaraju, Naveen and Daver, Naval G and Masarova, Lucia and Borthakur, Gautam and Chien, Kelly and Garris, Rebecca and Kantarjian, Hagop M},
  title = {A phase 2 trial of mini‐hyper‐ CVD , blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27463}
}
Kostenlos starten →